Introduction
Microparticles were originally identified from activated platelets prior appreciating their generation, upon activation, by several other cell types. Initial general wisdom was that microparticles were inert, hence cellular debris or bypass products of cell activation 1 ; however several recent studies have now described biological functions for these small particles which might therefore have a potential for impacting on patho-physiological processes, including ability to transfer packed information and promoting cell-to-cell crosstalk [1] [2] [3] .
Microparticles are heterogenous in their nature, even when produced from a single cell source, varying both in terms of content and size. When generated from cells entering in apoptosis (for a review see 1 ) or from activated leukocytes and platelets, microparticles are right side-out oriented, expressing phosphatidylserine, and specific patterns of membrane proteins which have been used to identify their cellular origin 4 ; for example, CD14, CD3, CD41a and CD146 are markers for monocyte-, lymphocyte-, platelet-and endothelial cell-derived microparticles, respectively 3 . The marker of PMN-derived microparticles is cell surface L-selectin (CD62L) and other proteins, including CD11b, whereas intracellular proteins detected in these microparticles include myeloperoxidase, elastase and other proteolytic enzymes 3 .
The release of microparticles from activated cells can be triggered by different stimuli; in all the different cases concisely listed above, microparticle generation is the end-point of an activation cascade requiring increases in intracellular calcium concentration, rearrangement of the cytoskeleton and the budding of these vesicles from the plasma membrane 1 .
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The present project stemmed from the notion that PMN-derived microparticles produce inhibitory effects when co-incubated with human monocyte-derived macrophages for up to 24 hours 1, 5 . Since human PMN contain high levels of the anti-inflammatory protein annexin 1 (AnxA1) 6 (representing between 2 and 4% of total cytosolic proteins 7 ), we questioned whether presence of AnxA1 could underlie some of the inhibitory effects of PMN-derived microparticles.
In fact, AnxA1 (37 kDa) is one of the effectors of endogenous anti-inflammation 8 , hence it contributes to the complex series of mechanisms activated in the host to keep under control cell activation and trafficking in the resolution of inflammation 9 .
There is ample experimental evidence that exogenously added AnxA1, as well as the endogenous protein, would inhibit PMN chemotaxis, activation and migration [10] [11] [12] [13] . Equally important, a large proportion of AnxA1 is contained in granules and vesicles 14, 15 , such that the protein is rapidly mobilised onto the PMN membrane compartment first, then PMN cell surface (and eventually released into the incubation medium) upon cell activation and adhesion 10, 12, 13 . On these bases, we reasoned there was adequate rationale to test whether PMN-derived microparticles would contain AnxA1, and if so, whether this mediator would contribute, at least in part, to their antiinflammatory/inhibitory properties.
Materials and Methods.
Unless otherwise specified, materials were obtained from Sigma-Aldrich Ltd (Poole, UK). PMN prepared by gradient separation 10 were added to unstimulated HUVEC monolayers in 6-well plates, routinely in the presence of 1 µM fMLP for 1 h at 37°C. In some cases, plateletactivating factor (0.1 µM) was used, with no different results (data not shown). In another protocol, freshly prepared PMN were not added to HUVEC, and rather kept in suspension for 1 h at 37°C. In all cases supernatants were collected and centrifuged at 4000xg for 5 min prior to further ultracentrifugation at 100,000xg for 1 h. Microparticle pellets were washed once and resuspended in PBS.
AnxA1 detection in microparticles
Western blotting. Microparticle extracts subjected to standard SDS-PAGE and transferred onto PVDF membranes (Millipore, Watford, UK). These were incubated with mAb 1B (1 µg/ml) and HRP-conjugated goat anti-mouse IgG (Dako, Cambridge, UK). Proteins were detected using ECL detection kit and visualized on Hyperfilm™ (Amersham Biosciences, UK).
Mass spectrometry. Proteins were separated by SDS-PAGE and the resulting gel stained with Coomassie blue dye: the 37kD band was excised and in-gel reduction, alkylation and digestion with trypsin performed prior to analysis 16 . The mass spectral data was processed into peak lists and searched against the Swiss Prot and NCBI non-redundant database using MASCOT software (Matrix Science, London, UK).
FACS analysis.
Microparticles were stained with the following mAb at 10 µg/ml: anti- In some experiments microparticles were washed once in PBS supplemented with EDTA (0.1 mM; 10 min) prior to immunostaining and FACS analysis.
Flow chamber assay.
The assay was performed as recently reported 18 . Microparticles were added to PMNs (8 min) prior to the actual flow experiment whereby 5x10 6 PMN (in 1 ml) were flown over HUVEC activated with TNF (10 ng/ml; 4 h); in either case, the total number of interacting cells was then quantified to determine the degree of cell capture, rolling and adhesion 18 . In some cases, PMN or microparticles were preincubated with neutralizing antibodies (5 min at 37°C), using a mouse anti-human ALX (5 µg/ml; clone 6C7-3) or anti-AnxA1 (10 µg/ml; mAb 1B), respectively; clone MCA928 (10 µg/ml; Serotec) used as isotype control.
Mouse PMN derived microparticles
For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From Murine PMNs were prepared from wild type and AnxA1 null mice 19 (backcrossed 10 times onto a Balb/c background) as described 20 . Briefly, bone marrows were extracted by flushing the tibias and femurs of 7 mice per group. Following extraction, and a PBS-wash, cells were extracted using a Percoll gradient 20 . Microparticles were produced by adding 5x10 6 . Airpouches were washed 4 h later and migrated PMN counted with light microscopy and stained with Gr1 (clone rb6-8c5; eBioscience, Wembley, UK) as described 19 .
Data handing and statistical analysis
In vitro experiments result from 4 independent experiments; in vivo PMN migration was performed in 5 mice per group. In all cases data are reported as mean ± SEM. Statistical
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Results

Presence of
These initial characterizations were completed by assessing the localization of AnxA1 in the microparticles. Washing them with PBS + EDTA remove >80% of immunoreactivity for the protein, as shown by comparison of Figure 3E with Figure 3F . Therefore, the large majority of AnxA1 is exposed on the microparticles surface, and it is not integral in the phospholipids bilayer.
PMN derived microparticles inhibits PMN/HUVEC interaction under flow
We Since AnxA1 inhibitory actions on the PMN are brought about by activation of the antiinflammatory receptor termed ALX 18, 23, 24 , the effects of a neutralizing anti-ALX mAb was tested: this tool was also effective in abrogating the inhibitory effects of microparticles on PMN capture and adhesion ( Figure 5 ).
Anti-inflammatory actions of PMN-derived microparticles
In the last section of the study, we tested -for the first time -whether PMN-derived 
Discussion
We report here that PMN-derived microparticles contain the anti-inflammatory protein AnxA1, and that this mediator of endogenous anti-inflammation confers them inhibitory properties on the process of leukocyte/endothelium interaction under flow; in addition, administration to mice of these microparticles reduced PMN trafficking in response to local cytokine application, and this effect was reliant on AnxA1, as determined by testing microparticles from AnxA1 null PMN.
Initial reports of microparticles indicated their likely 'bystander' nature, i.e. that they were generated by cells entering into apoptosis as a sort of terminal act, safely releasing potentially toxic molecules in enclosed particles (reviewed in 1 ). However, the observations that microparticles were generated from activated cells, even in the absence of programmed cell death, was the first indication that they might solve specific biological function(s). The last few years have witnessed a proliferation of studies investigating the components of microparticles 1, 4 ; their cell-specific peculiarities 3 ; their potential role in cell-to-cell crosstalk 1, 26 , and their detection in the plasma patients suffering from inflammatory diseases 2,3 . Therefore, it is possible we have so far just identified very few of the potential biological properties of microparticles; this may be particularly true when we consider their variety in sizes and components, as well as variety in relation to their cell source. Here we addressed our attention to PMN-derived microparticles.
In the context of experimental inflammation we have pioneered the focus on anti-inflammation, addressing in particular the role played by the homeostatic mediator AnxA1. Human and rodent neutrophils have high cytoplasmic levels of this protein, which is augmented in response to both glucocorticoid and cytokines 25 . During the initial phases of the leukocyte migration response AnxA1 translocates to the plasma membrane 10 , interacts with a specific G-protein couple receptor 23 to control their extent and rate of emigration into the sub-endothelial tissue space, towards the inflammatory site 11, 25 . Therefore, the "annexin 1 pathway" as a whole becomes operative within the microenvironment of an adherent PMN. Disruption of this system, achieved with the global AnxA1 -/-mouse colony, leads to altered pathology as determined in relevant experimental models, including stroke and multiple organ failure post-endotoxaemia 25, 27 . In addition, blood neutrophils taken from these mice display higher degrees of activation in response to classical leukocyte stimulants (e.g. PAF or fMLP) 11 .
AnxA1 lacks a signal peptide 28 nonetheless is abundantly released from activated PMN 10, 12, 29 .
We proposed that the rapid mobilization of AnxA1 observed in activated PMN was consequent to intracellular granule mobilization, since a good proportion of the protein is contained in gelatinase granules 14 , a finding firstly confuted 30 , but then confirmed by proteomic analyses 15 .
The data here presented indicate that AnxA1 could be released from activated PMN via the 'microparticle pathway', so that multiple ways of mobilizing the protein from this cell type might exist. AnxA1 will not be a unique protein or mediator to follow multiple manners of release, since also CD62L, for instance, can be shed as soluble protein or also embedded in phosphatidylserine positive microparticles 4 . Such a dichotomy of secretion (soluble and microparticle-associated) mechanism has also been proposed for the short-lived lipid plateletactivating factor 31 . Another analogy for this mode of secretion of AnxA1 would be with IL-1β 32 : like AnxA1, this cytokine lacks a signal peptide 33 , nonetheless it is released from activated
For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From cells, and microparticles are the route identified in monocytic cells 1, 32 . We would propose that release of pivotal proteins from activated cells via microparticle formation could be a relatively more general process in inflammatory cell patho-biology. Since apoptotic cells release microparticles, we would predict that AnxA1 release via this pathway could be responsible for its augmenting property of the phagocytosis of apoptotic PMN by macrophages 34 . In any case, by analogy to the studies where the inhibitory and anti-inflammatory properties of human recombinant AnxA1 have been dissected (e.g. see 6 ), the presence of AnxA1 PMN-derived microparticles led us to hypothesise that these microparticles could exert inhibitory properties on the PMN extravasation process.
Then, we tested the functionality of PMN-derived microparticles using the flow chamber assays.
Static assays have established that human recombinant AnxA1 can inhibit PMN chemotaxis 12 , adhesion to 13 , and transmigration through, endothelial monolayers 10 . In addition, the protein would inhibit PMN/HUVEC adhesion under flow, an effect reliant on activation of the specific AnxA1 receptor, termed ALX
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. Incubation of PMN-derived microparticles exerted a marked inhibition on PMN capture onto the HUVEC monolayer, this resulting from an inhibition of both PMN rolling and adhesion. Of interest, neutralization strategies against endogenous AnxA1 or its receptor ALX produced a selective abrogation of the inhibitory effect of microparticles on PMN adhesion, with no effect on rolling. This is strikingly reminiscent of the selective inhibition produced by human recombinant AnxA1, able to inhibit PMN adhesion, but not rolling, when co-incubated with PMN prior to flow 18 . Therefore, AnxA1 expressed or exposed by PMNderived microparticles is biologically active, replicating the properties described for exogenous addition of the protein. Moreover, the model that emerges from these studies is the one where AnxA1, presented by the microparticles, would activate ALX expressed on the recipient PMN, diminishing its reactivity with the HUVEC monolayer. These data identify the AnxA1/ALX pathway as a major checkpoint mechanism, devoted to the rapid control of the extent of PMN/HUVEC interaction.
Equally convincingly, these data indicate that microparticle effect upon PMN rolling is not AnxA1 mediated. It is possible that CD62L -expressed by all PMN-derived microparticles 4 -might be responsible for this action, since blockade of this selectin affects PMN rolling, as determined in similar experimental conditions 18 . However, it is more likely that other mediators are causing this inhibitory effect, since microparticles derived from resting PMN did contain CD62L, yet were not able to significantly attenuate the extent PMN rolling. Proteomic profiling of microparticles derived from differently activated PMN will shed light on these puzzling data.
These data produced with the flow chamber assay are in apparent contrast with an earlier report 35 , where overnight incubation of PMN-derived microparticles produced an activating phenotype of the HUVEC. Gasser et al have commented on this discrepancy 5 , and we would agree that Finally, we tested whether PMN-derived microparticles could produce anti-inflammatory actions on the process of in vivo PMN trafficking. The mouse airpouch model inflamed with IL-1β was chosen, since exquisitely sensitive to the inhibitory actions of human recombinant AnxA1 and its bioactive peptides 22 ; in addition, agonism at the murine ortologue of ALX produced potent inhibitory effects on the extent of PMN migration 23, 36 . Injection into the air-pouches of IL-1β
produced the expected influx of PMN reliably assessed at the 4 h time-point 22 . Administration to mice of doses ranging from 40 to 90x10 3 microparticles inhibited PMN trafficking, with the murine ones being more effective than the ones generated from human PMN; however the two 'species' of microparticles did not display qualitatively different properties, both being able to significantly attenuate PMN influx in response to cytokine injection. To assess the potential role of microparticle-associated AnxA1 in these actions, we resorted to the use of microparticles produced from AnxA1 null PMN: the data obtained strongly indicated a functional role for this endogenous effectors of anti-inflammation in bringing about the anti-migratory effect of microparticles. We did not dissect, here, which specific step of the leukocyte recruitment process is chiefly affected by the microparticles; future studies will rely on the technique of intravital microscopy, with the use of protocols successfully employed to assess the actions of exogenous and endogenous AnxA1 11, 37 , to address this specific question.
In conclusion we report several novel features of PMN microparticles, describing for the first time their expression of AnxA1; this homeostatic protein, likely interacting with its receptor ALX, is functionally active in modulating human PMN reactivity with activated HUVEC. In addition, PMN-derived microparticles, delivered by intravenous administration, display potent anti-migratory properties. Again, such action is relying on their AnxA1 content as demonstrated by using microparticles prepared from AnxA1 null mice. These results prompt us to speculate that generation of AnxA1-rich microparticle production within the inflamed microcirculation, 
